The North America Heparin Market would witness market growth of 5.8% CAGR during the forecast period (2021-2027).
The chemical formula of heparin is C12H19NO20S3 and it refers to a sulfur-containing polysaccharide, naturally produced in the human body. It behaves as an anticoagulant which means a blood-thinning chemical. It doesn’t allow the formation of blood clots in blood vessels. Thus, it is used in the treatment of heart conditions and unstable angina. Heparin is also administered post-surgeries, and during dialysis, & blood transfusion. By its chemical reactions, it breaks up clots and maintains the fluidity of the blood. Also, there are some side-effects of using heparin such as easy bruising and redness & itchy skin. Heparin acts as a blood thinner. Chemically, it is a disaccharide anticoagulant compound that eliminates the formation of blood clots. It is produced by mast cells and basophils.
There are increasing incidences of cardiovascular diseases across the world, including heart attacks and strokes which will create opportunities for the market players. According to American Heart Association (AHA) Heart Disease and Stroke Statistics, it is estimated that in 2019, more than 5.3 million Americans suffered from atrial fibrillation. The increasing demand for heparin among cardiac patients will further drive the heparin market.
According to the factsheet of the Population Reference Bureau, the number of Americans aging 65 years or more is likely to get double by the end of 2060. So, the older age group in the total population is expected to increase from 16% to 23%. The geriatric population is at greater risk of chronic diseases. It is expected to have a positive impact on the heparin market. The increasing cases of sports injury and cardiovascular disorders are boosting the demand for heparin in the USA. Moreover, high patient awareness and sophisticated healthcare infrastructure in North America are some of the factors that can be attributed to the growth of the market in this region. Also, the prevalence of cardiovascular diseases including pulmonary embolism is high among the geriatric population of the USA. Thus, there is higher adoption of advanced heparin products in this region which is expected to drive the growth of the heparin market during the forecast period.
The US market dominated the North America Unfractionated Heparin Market by Country 2020, thereby, achieving a market value of $466.7 million by 2027. The Canada market is experiencing a CAGR of 7.5% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 6.6% during (2021 - 2027).
Based on Type, the market is segmented into Low Molecular Weight Heparin, Unfractionated Heparin and Ultra-low Molecular Weight Heparin. Based on Application, the market is segmented into Atrial Fibrillation, Coronary Artery Disease, Venous Thromboembolism, Renal Impairment and Other Applications. Based on Route of Administration, the market is segmented into Subcutaneous and Intravenous. Based on End Use, the market is segmented into Outpatient and Inpatient. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Heparin Market is Estimated to Reach USD 10 Billion by 2027 at a CAGR of 6.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Baxter International, Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Pfizer, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S, and Viatris, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Usability
- Average-type
- Premium-type
- Low-type
By Product
- Surgical Gowns
- Patient Gowns
- Non-surgical Gowns
By Risk Type
- Moderate risk Gowns
- High risk Gowns
- Low risk Gowns
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Baxter International, Inc.
- B. Braun Melsungen AG
- Fresenius SE & Co. KGaA
- Pfizer, Inc.
- Sanofi S.A.
- Teva Pharmaceuticals Industries Ltd.
- Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
- Dr. Reddy’s Laboratories Ltd.
- LEO Pharma A/S
- Viatris, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Heparin Market, by Type
1.4.2 North America Heparin Market, by Application
1.4.3 North America Heparin Market, by Route of Administration
1.4.4 North America Heparin Market, by End Use
1.4.5 North America Heparin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Heparin Market by Type
3.1 North America Low Molecular Weight Heparin Market by Country
3.2 North America Unfractionated Heparin Market by Country
3.3 North America Ultra-low Molecular Weight Heparin Market by Country
Chapter 4. North America Heparin Market by Application
4.1 North America Atrial Fibrillation Market by Country
4.2 North America Coronary Artery Disease Market by Country
4.3 North America Venous Thromboembolism Market by Country
4.4 North America Renal Impairment Market by Country
4.5 North America Other Applications Market by Country
Chapter 5. North America Heparin Market by Route of Administration
5.1 North America Subcutaneous Market by Region
5.2 North America Intravenous Market by Region
Chapter 6. North America Heparin Market by End Use
6.1 North America Outpatient Market by Country
6.2 North America Inpatient Market by Country
Chapter 7. North America Heparin Market by Region
7.1 US Heparin Market
7.1.1 US Heparin Market by Type
7.1.2 US Heparin Market by Application
7.1.3 US Heparin Market by Route of Administration
7.1.4 US Heparin Market by End Use
7.2 Canada Heparin Market
7.2.1 Canada Heparin Market by Type
7.2.2 Canada Heparin Market by Application
7.2.3 Canada Heparin Market by Route of Administration
7.2.4 Canada Heparin Market by End Use
7.3 Mexico Heparin Market
7.3.1 Mexico Heparin Market by Type
7.3.2 Mexico Heparin Market by Application
7.3.3 Mexico Unfractionated Heparin Market by Route of Administration
7.3.4 Mexico Heparin Market by End Use
7.4 Rest of North America Heparin Market
7.4.1 Rest of North America Heparin Market by Type
7.4.2 Rest of North America Heparin Market by Application
7.4.3 Rest of North America Heparin Market by Route of Administration
7.4.4 Rest of North America Heparin Market by End Use
Chapter 8. Company Profiles
8.1 Baxter International, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.2 B. Braun Melsungen AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 Fresenius SE & Co. KGaA
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.1 Recent strategies and developments:
8.3.1.1 Partnerships, Collaborations, and Agreements:
8.3.1.2 Acquisition and Mergers:
8.3.1.3 Product Launches and Product Expansions:
8.4 Pfizer, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.5 Sanofi S.A.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.6 Teva Pharmaceutical Industries Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.7 Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
8.7.1 Company Overview
8.8 Dr. Reddy’s Laboratories Ltd.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 LEO Pharma A/S
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
TABLE 1 North America Heparin Market, 2017 - 2020, USD Million
TABLE 2 North America Heparin Market, 2021 - 2027, USD Million
TABLE 3 North America Heparin Market by Type, 2017 - 2020, USD Million
TABLE 4 North America Heparin Market by Type, 2021 - 2027, USD Million
TABLE 5 North America Low Molecular Weight Heparin Market by Country, 2017 - 2020, USD Million
TABLE 6 North America Low Molecular Weight Heparin Market by Country, 2021 - 2027, USD Million
TABLE 7 North America Unfractionated Heparin Market by Country, 2017 - 2020, USD Million
TABLE 8 North America Unfractionated Heparin Market by Country, 2021 - 2027, USD Million
TABLE 9 North America Ultra-low Molecular Weight Heparin Market by Country, 2017 - 2020, USD Million
TABLE 10 North America Ultra-low Molecular Weight Heparin Market by Country, 2021 - 2027, USD Million
TABLE 11 North America Heparin Market by Application, 2017 - 2020, USD Million
TABLE 12 North America Heparin Market by Application, 2021 - 2027, USD Million
TABLE 13 North America Atrial Fibrillation Market by Country, 2017 - 2020, USD Million
TABLE 14 North America Atrial Fibrillation Market by Country, 2021 - 2027, USD Million
TABLE 15 North America Coronary Artery Disease Market by Country, 2017 - 2020, USD Million
TABLE 16 North America Coronary Artery Disease Market by Country, 2021 - 2027, USD Million
TABLE 17 North America Venous Thromboembolism Market by Country, 2017 - 2020, USD Million
TABLE 18 North America Venous Thromboembolism Market by Country, 2021 - 2027, USD Million
TABLE 19 North America Renal Impairment Market by Country, 2017 - 2020, USD Million
TABLE 20 North America Renal Impairment Market by Country, 2021 - 2027, USD Million
TABLE 21 North America Other Applications Market by Country, 2017 - 2020, USD Million
TABLE 22 North America Other Applications Market by Country, 2021 - 2027, USD Million
TABLE 23 North America Heparin Market by Route of Administration, 2017 - 2020, USD Million
TABLE 24 North America Heparin Market by Route of Administration, 2021 - 2027, USD Million
TABLE 25 North America Subcutaneous Market by Region, 2017 - 2020, USD Million
TABLE 26 North America Subcutaneous Market by Region, 2021 - 2027, USD Million
TABLE 27 North America Intravenous Market by Region, 2017 - 2020, USD Million
TABLE 28 North America Intravenous Market by Region, 2021 - 2027, USD Million
TABLE 29 North America Heparin Market by End Use, 2017 - 2020, USD Million
TABLE 30 North America Heparin Market by End Use, 2021 - 2027, USD Million
TABLE 31 North America Outpatient Market by Country, 2017 - 2020, USD Million
TABLE 32 North America Outpatient Market by Country, 2021 - 2027, USD Million
TABLE 33 North America Inpatient Market by Country, 2017 - 2020, USD Million
TABLE 34 North America Inpatient Market by Country, 2021 - 2027, USD Million
TABLE 35 North America Heparin Market by Region, 2017 - 2020, USD Million
TABLE 36 North America Heparin Market by Region, 2021 - 2027, USD Million
TABLE 37 US Heparin Market, 2017 - 2020, USD Million
TABLE 38 US Heparin Market, 2021 - 2027, USD Million
TABLE 39 US Heparin Market by Type, 2017 - 2020, USD Million
TABLE 40 US Heparin Market by Type, 2021 - 2027, USD Million
TABLE 41 US Heparin Market by Application, 2017 - 2020, USD Million
TABLE 42 US Heparin Market by Application, 2021 - 2027, USD Million
TABLE 43 US Heparin Market by Route of Administration, 2017 - 2020, USD Million
TABLE 44 US Heparin Market by Route of Administration, 2021 - 2027, USD Million
TABLE 45 US Heparin Market by End Use, 2017 - 2020, USD Million
TABLE 46 US Heparin Market by End Use, 2021 - 2027, USD Million
TABLE 47 Canada Heparin Market, 2017 - 2020, USD Million
TABLE 48 Canada Heparin Market, 2021 - 2027, USD Million
TABLE 49 Canada Heparin Market by Type, 2017 - 2020, USD Million
TABLE 50 Canada Heparin Market by Type, 2021 - 2027, USD Million
TABLE 51 Canada Heparin Market by Application, 2017 - 2020, USD Million
TABLE 52 Canada Heparin Market by Application, 2021 - 2027, USD Million
TABLE 53 Canada Heparin Market by Route of Administration, 2017 - 2020, USD Million
TABLE 54 Canada Heparin Market by Route of Administration, 2021 - 2027, USD Million
TABLE 55 Canada Heparin Market by End Use, 2017 - 2020, USD Million
TABLE 56 Canada Heparin Market by End Use, 2021 - 2027, USD Million
TABLE 57 Mexico Heparin Market, 2017 - 2020, USD Million
TABLE 58 Mexico Heparin Market, 2021 - 2027, USD Million
TABLE 59 Mexico Heparin Market by Type, 2017 - 2020, USD Million
TABLE 60 Mexico Heparin Market by Type, 2021 - 2027, USD Million
TABLE 61 Mexico Heparin Market by Application, 2017 - 2020, USD Million
TABLE 62 Mexico Heparin Market by Application, 2021 - 2027, USD Million
TABLE 63 Mexico Unfractionated Heparin Market by route of administration, 2017 - 2020, USD Million
TABLE 64 Mexico Unfractionated Heparin Market by route of administration, 2021 - 2027, USD Million
TABLE 65 Mexico Heparin Market by end use, 2017 - 2020, USD Million
TABLE 66 Mexico Heparin Market by end use, 2021 - 2027, USD Million
TABLE 67 Rest of North America Heparin Market, 2017 - 2020, USD Million
TABLE 68 Rest of North America Heparin Market, 2021 - 2027, USD Million
TABLE 69 Rest of North America Heparin Market by Type, 2017 - 2020, USD Million
TABLE 70 Rest of North America Heparin Market by Type, 2021 - 2027, USD Million
TABLE 71 Rest of North America Heparin Market by Application, 2017 - 2020, USD Million
TABLE 72 Rest of North America Heparin Market by Application, 2021 - 2027, USD Million
TABLE 73 Rest of North America Heparin Market by Route of Administration, 2017 - 2020, USD Million
TABLE 74 Rest of North America Heparin Market by Route of Administration, 2021 - 2027, USD Million
TABLE 75 Rest of North America Heparin Market by End use, 2017 - 2020, USD Million
TABLE 76 Rest of North America Heparin Market by End Use, 2021 - 2027, USD Million
TABLE 77 Key Information – Baxter International, Inc.
TABLE 78 key Information – B. Braun Melsungen AG
TABLE 79 key information – Fresenius SE & Co. KGaA
TABLE 80 Key Information – Pfizer, Inc.
TABLE 81 Key Information – Sanofi S.A.
TABLE 82 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 83 key information – Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
TABLE 84 key information – Dr. Reddy’s Laboratories Ltd.
TABLE 85 key information – LEO Pharma A/S
TABLE 86 key information – Viatris, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Fresenius SE & Co. KGaA